hat
Liothyronine kapab tou prefere pou pasyan ki gen koma myxedema paske nan pi rapid li yo kòmansman nan aksyon lè yo konpare ak levothyroxine. Low-dòz liothyronine yo te montre amelyore sentòm depresyon nan pasyan ki gen fonksyon tiwoyid nòmal ki pa gen ase sekou nan depresyon yo apre yo fin eseye plizyè depresè diferan. Lè yo te ajoute nan medikaman ki deja egziste, liothyronine te ede reyalize remisyon nan 24% nan pasyan ki patisipe nan yon pati nan gwo jijman STAR * D depresyon an.Dapre yon meta-analiz 2001 ki analize efikasite nan ajoute Liothyronine nan depresè tricyclic, fanm an patikilye pouvwa benefisye de Liothyronine.
eng
Liothyronine may also be preferred for patients with myxedema coma because of its quicker onset of action when compared to levothyroxine. Low-dose liothyronine has been shown to improve depression symptoms in patients with normal thyroid function who do not have adequate relief from their depression after trying several different antidepressants. When added to existing medications, liothyronine helped achieve remission in 24% of patients participating in a subset of the large STAR*D depression trial.According to a 2001 meta-analysis that analyzed the effectiveness of adding Liothyronine to tricyclic antidepressants, women in particular may benefit from Liothyronine.